Status:
RECRUITING
The Clinical Impact of Cobas® Eplex Blood Culture Panels for the Diagnosis of Bacteremia and Fungemia
Lead Sponsor:
University Hospital, Antwerp
Collaborating Sponsors:
Roche Diagnostics GmbH
Conditions:
Bloodstream Infection
Eligibility:
All Genders
Phase:
NA
Brief Summary
A quality improvement study on the diagnostics and clinical management of bloodstream infection episodes. Patients of all ages and genders with positive blood cultures collected for standard patient c...
Detailed Description
Bloodstream infections (BSIs) impose a considerable burden on patients and healthcare systems due to the need for hospital admission, extended stays, additional diagnostic tests and specific treatment...
Eligibility Criteria
Inclusion
- Patients with onset of BSI at the emergency department or general wards
- Patients hospitalized from blood draw (at least 24h)
- For pediatric patient only BSI episodes caused by gram-negative organisms
Exclusion
- Patients deceased at the time of the positive blood culture
- Patients in comfort care or with an estimated survival before sepsis of less than one month
- Patients with positive blood culture bottles within the past 14 days
- Patients for which the blood bottles are highly suspected of contaminants (bacterial species belonging to potential skin commensals or known environmental contaminants) and in the absence of any other site of infections.
Key Trial Info
Start Date :
November 19 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06576258
Start Date
November 19 2024
End Date
December 1 2025
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Antwerp
Edegem, Antwerp, Belgium, 2650